期刊文献+

HPLC法测定血浆和肺部组织、体液中左氧氟沙星浓度 被引量:2

Determination of the concentration of levofloxacin in plasma and tissues and body fluids of lung by high performance liquid chromatography
下载PDF
导出
摘要 目的建立测定血浆、肺组织、支气管黏膜、肺泡灌洗液和痰液中左氧氟沙星浓度的方法。方法固定相为TSK-gel ODS-80TM C18柱(150mm×4.6mm,5μm);流动相为50mmol·L^-1 KH2PO4(pH2.O)四氢呋喃-1mol·L^-1醋酸铵(92/7/1,V/V/V);荧光检测波长Ex/Em为296/504mm,流速1.0mL·min^-1。结果各质控浓度的血浆、肺组织、支气管黏膜、肺泡灌洗液和痰液中左氧氟沙星的萃取回收率分别为94.2%-98.4%、100.2%~103.7%、99.3%~100.5%、99.9%~102.2%和100.6%-100.9%。各质控浓度的血浆、肺泡灌洗液、痰液和缓冲液测定结果日内RSD分别≤3.6%、≤5.3%、≤5.2%和≤1.7%,方法回收率分别为91.5%~110%、96.7%~100.5%、99.5%~103.8%和96.3%~103%;日间RSD分别≤3.5%、≤6.3%、≤6.3%和≤4.1%。血浆、肺泡灌洗液、痰液和缓冲液中左氧氟沙星质量浓度为0.01~5.00mg·L^-1时具有良好的线性关系(r=0.9996~0.9999)。左氧氟沙星在上述组织体液中最低检测限浓度为0.01mg·L^-1。结论本试验建立的HPLC方法灵敏准确、特异性高,可用于测定血浆、肺组织、支气管黏膜、肺泡灌洗液和痰液中左氧氟沙星的浓度。 AIM To establish the high performance liquid chromatography (HPLC) method for detmination of the concentration of levofloxacin in plasma, lung, bronchus membrane, bronchoalveolar lavage fluid (BALF) and sputum. METHODS The HPLC was peffonned on TSK-gel ODS-80TM Cl8 ( 150 mm× 4.6 mm, 5μm) columm. The mobile phase consisted of 50 mmol· L^-1 KH2PO4 (pH 2.0)-tetrahydrofuran-1 mol ·L^-1 CH3COONH4(92/7/1, V/V/V). The detection wavelength(Ex/Em)wassetat296nm/504nm.The flow rate was 1.0 mL·min^-1. RESULTS The extraction recovery of each quality control concentration of plasma, lung, bronchus membrane, BALF and sputum was 94.2% - 98.4%, 100.2% - 103.7%, 99.3% - 100.5%, 99.9% - 102.2% and 100.6% - 100.9%, respectively. The inter-day coefficient variation of each quality control concentration of plasma, BALF, sputum and buffer was less than 3.6%,5.3%, 5.2% and 1.7%, respectively. The method recovery was 91.5% - 110%, 96.7% - 100.5%, 99.5% - 103.8% and 96.3% - 103% ,respectively. The intra-day coefficient variation was less than 3.5%, 6.3%, 6.3% and 4.1% ,respectively. A good linearity was shown in the concentration range 0.01 - 5.00 mg·L^-1 for all constituents ( r = 0.999 6 - 0.999 9). The minimum detection limit concerttration of levofloxacin in above tissues and body fluids was 0.01 mg· L^-1. CONCLUSION The method of establishment is sensitive, accurate and has a high specificity.It is a suitable method for determining the drug concentration of levofloxacin in plasma , lung, bronchus membrane, BALF and sputum.
出处 《中国临床药学杂志》 CAS 2008年第3期158-162,共5页 Chinese Journal of Clinical Pharmacy
关键词 左氧氟沙星 肺组织 支气管黏膜 肺泡灌洗液 levofloxacin lung tissue bronchus membrane bronchoalveolar lavage fluid sputum
  • 相关文献

参考文献6

二级参考文献23

  • 1李光辉,朱德妹,张婴元,汪复.上海地区部分医院血培养分离菌的分布及耐药性[J].中国抗感染化疗杂志,2004,4(4):193-198. 被引量:27
  • 2沈定霞,罗燕萍,崔岩,赵莉萍,白立彦.分离产金属β-内酰胺酶的铜绿假单胞菌[J].中华医院感染学杂志,2004,14(1):86-88. 被引量:109
  • 3崔俊昌,刘又宁,王睿,梁蓓蓓,裴斐,郑专杰.4种氟喹诺酮类药物对金黄色葡萄球菌的防耐药变异浓度[J].中华医学杂志,2004,84(22):1863-1866. 被引量:34
  • 4肖永红.抗菌药物的药代动力学/药效学概念及其临床意义[J].中华医学杂志,2004,84(22):1914-1915. 被引量:36
  • 5Desjardin LE ,Chen Y,Perkins MD,et al.Comparison of the ABI 7700 system(TaqMan) and competitive PCR for Quantification of IS6100 DNA in sputum during treatment of tuberculosis[J]. Clin Microbiol,1998,36:1964.
  • 6AL Zahrani K, AL Jahdali H, Poirier L, et al. Accuracy and utility of commercially available amplification and serolongic tests for the diagnosis of minimal pulmonary tuberculosis[J].Am J Respir Crit Care Med,2000,162:1323.
  • 7Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy, 2001, 21(10 Pt 2):233S-252S.
  • 8Graninger W, Zeitlinger M. Cinical applications of levofloxacin for severe infections. Chemotherapy, 2004, 50 Suppl 1:16-21.
  • 9Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother, 1997, 41:2256-2260.
  • 10Furlanut M, Brollo L, Lugatti E, et al. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother, 2003, 51:101-106.

共引文献65

同被引文献18

  • 1李见春,马涛,祝晓光,蒋志文.盐酸左氧氟沙星胶囊人体药物动力学与生物利用度研究[J].蚌埠医学院学报,2006,31(4):417-419. 被引量:6
  • 2Muller M, dela Pefla A, Derendorf H. Issues ir pharmacokinetics and pharmacodynamics of anti infectiv( agents:distribution in tissue. Antim~,crob Agents Chemother, 2001,,18:1441-1453.
  • 3Zeitlinger MA, Erovic BM, Saucrmann R, et al. Plasmaconcentralions might lead to overestimation of target site activity of piperacillin in patients with sepsis. J Antimicrob Chemother,2005,56:703-708.
  • 4Yamazaki K, Ogura S, Ishizaka A, et al. Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. Am J Respir Crit Care Med, 2003,168: 1304-1307.
  • 5EffrosRM.用呼出气冷凝液检测肺部炎症//急性呼吸窘迫综合征.白春学,孙波.上海:复旦大学出版社,2005:107-115.
  • 6Montuschi P. Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. Ther Adv Respir Dis, 2007,1 : 5-23.
  • 7Bayley DI., Abusriwil H, Ahmad A, et al. Validation of assays for inflammatory mediators in exhaled breath condensate. Eur Respir J,2008,31:943-948.
  • 8Rosias PP, Robroeks CM, Kester A, et al. Biomarker reproducibility in exhaled breath condensate collected with different condensers. Eur Respir J, 2008,31 : 934-942.
  • 9Zhang J, Xie X, Zhou X, et al. Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. J Clin Pharmacol, 2010, 50 : 922-928.
  • 10Balbi B, Pignatti P, Corradi M, et al. Bronehoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers ~ values in healthy adults. Eur Respir J, 2007,30 : 769 -781.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部